We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Novo, Sandoz Reach Deal Over Generic Prandin

Law360 (December 17, 2010, 1:15 PM EST) -- Novo Nordisk Inc. has agreed to drop infringement allegations against Sandoz Inc. over two claims of a patent for diabetes drug Prandin, in exchange for Sandoz's admission that it infringed three other claims.

The agreement, signed Thursday by Judge Paul G. Gardephe in the U.S. District Court for the Southern District of New York, stipulates resolution on all five claims of Novo-held U.S. Patent Number 6,677,358, the only patent asserted in the suit.

The '358 patent, titled “NIDDM regimen,” describes a short-acting oral hypoglycemic agent used...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.